Head-to-head · WeighScore
FuturHealth vs Layla
The verdict
Layla takes it — 70.9/100 to 65.6/100.
Layla grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Layla is a US telehealth weight-loss program built around semaglutide, offering compounded semaglutide as injections and as oral dropper drops, plus compounded tirzepatide and a brand-inclusive GLP-1…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | FuturHealth | Layla |
|---|---|---|
| WeighScore | 65.6/100 | 70.9/100 |
| Grade | C | C |
| Scorecard rank | #215 | #101 |
| Semaglutide | $199/mo (compounded) | $237/mo (all doses, compounded) |
| Tirzepatide | Not disclosed | $199/mo (all doses, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
Graded #215 · C
Strengths
- LegitScript Certified and HITRUST Certified
- Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
- Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
- Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths
Where it loses points
- Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
- BBB complaints describe recurring charges without medication received — confirm cancellation flow first
- Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
- Pricing not shown until after the qualification questionnaire or portal login
- Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
Graded #101 · C
Strengths
- Oral semaglutide dropper option plus injectable semaglutide and tirzepatide, with a brand-name upgrade path
- Named Medical Director (Dr. Ruth Cohen) and 24-7 doctor messaging
- Quiz-based intake with fast three to five day shipping
Where it loses points
- Brand-inclusive GLP-1 program is expensive, starting around 1,299 dollars
- States served are not published on the site
- Support phone line uses a UK format, and the compounding pharmacy is not named
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.